IGF1R and soft tissue sarcoma: The most obvious biomarker would be expression of the IGF-1R, but a Phase 2 trial with Cixutumumab (IGF-1R antibody) and Temsirolimus (mTOR inhibitor) in patients with bone and soft-tissue sarcomas showed that IGF-1R expression does not correlate with therapeutic response [11].